U-PLEX®

NHP M-CSF



www.mesoscale.com®

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com

Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K15068M, K25068M	U-PLEX Biomarker Group 1 (NHP)
Singleplex	K156XRK-1/-2/-4	U-PLEX NHP M-CSF Assay with SECTOR™ plates
	K156XRK-21/-22/-24	U-PLEX NHP M-CSF Assay with QuickPlex® plates
	K256XRK-2/-4	U-PLEX NHP M-CSF Assay with 384-well plates
Antibody Set	B21XR-2/-3	U-PLEX Human M-CSF Antibody Set
Assay Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX NHP M-CSF Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available in 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
M-CSF	0.29	0.28-0.37

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5X the standard deviations above the background (zero Calibrator).

Precision

	Control	Average Conc. (pg/mL)	Average Intra-run Conc. %CV	Inter-run Conc. %CV
M-CSF	High	236	3.0	7.5
	Mid	63	3.7	7.6
	Low	15	4.0	8.9

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

Spike Recovery

		Serum (N=5)		Plasma (N=5)		Cell Culture Media (N=5)	
	Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
Cynomolgus Monkey	High	72	64-80	68	26-86	101	99-103
	Mid	79	73-87	65	25-83	104	99-109
	Low	78	75-80	55	21-71	104	93-114
Rhesus Monkey	High	92	83-102	70	68-74	101	99-103
	Mid	95	87-101	73	66-77	104	99-109
	Low	84	81-89	78	73-83	104	93-114

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator at 3 levels. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Tested Samples

	Sample Type	Serum (N=11)	Plasma (N=11)	Cell Culture Media (N=10)
Cynomolgus Monkey	Median (pg/mL)	65	12	6.4
	Range (pg/mL)	17-122	4.0-30	0.56-80
	% Detected	100	100	100
Rhesus Monkey	Median (pg/mL)	22	17	20
	Range (pg/mL)	1.6-30	12-77	7.2-110
	% Detected	100	100	100

Normal serum, EDTA plasma, and cell culture media were diluted 2-fold prior to the assay.

Dilution Linearity

	Serum (N=5)			Plasma (N=5)			Cell Culture Media (N=5)		
	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
Cynomolgus Monkey	2	136	124-157	2	113	109-116	2	92	79-99
	4	138	127-152	4	115	108-121	4	91	87-96
	8	152	132-166	8	124	112-135	8	84	81-88
Rhesus Monkey	2	120	103-135	2	115	109-119	2	92	79-99
	4	122	95-152	4	116	111-119	4	91	87-96
	8	130	99-160	8	120	116-127	8	84	81-88

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator and tested at different dilutions. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the M-CSF Antibody Set was tested individually against a larger panel of recombinant human analytes for nonspecific binding (CTACK, Eotaxin, Eotaxin-2, Eotaxin-3, ENA-78, FLT3L, Fractalkine, G-CSF, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17B, IL-17C, IL-17D, IL-17F, IL-18, IL-22, IL-23, IP-10, I–TAC, MCP-1, MCP-2, MCP-3, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-3α, MIP-3β, MIP-5, SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, VEGF-A, and YKL-40). Nonspecific binding was less than 0.5%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

Diluents 57 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: M-CSF is included in Calibrator 10. The full-length recombinant protein is expressed in *E. coli*.
Antibodies: The U-PLEX NHP M-CSF Assay uses a mouse monoclonal antibody for capture and a goat polyclonal antibody for detection.
Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently than the representative data shown.